These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33878788)

  • 1. Differential Effects of Various Androgens on Polycystic Ovary Syndrome.
    de Medeiros SF; Barbosa BB; de Medeiros AKLWY; de Medeiros MAS; Yamamoto MMW
    Horm Metab Res; 2021 May; 53(5):341-349. PubMed ID: 33878788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome.
    Medeiros SF; Barbosa BB; Medeiros MAS; Yamamoto AKLW; Yamamoto MMW
    Rev Bras Ginecol Obstet; 2022 Feb; 44(2):142-153. PubMed ID: 35213912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
    Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
    J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dehydroepiandrosterone sulfate and free androgen index on pregnancy and neonatal outcomes in PCOS patients.
    Zhao W; Li Z; Cai B; Zhou C; Mai Q
    Reprod Biol Endocrinol; 2024 Apr; 22(1):43. PubMed ID: 38627777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
    Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
    Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
    Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
    Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DHEA, DHEAS and PCOS.
    Goodarzi MO; Carmina E; Azziz R
    J Steroid Biochem Mol Biol; 2015 Jan; 145():213-25. PubMed ID: 25008465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
    Chen MJ; Han DS; Yang JH; Yang YS; Ho HN; Yang WS
    Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China.
    Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W
    J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial.
    Mai K; Bobbert T; Reinecke F; Andres J; Maser-Gluth C; Wudy SA; Möhlig M; Weickert MO; Hartmann MF; Schulte HM; Diederich S; Pfeiffer AF; Spranger J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3900-6. PubMed ID: 18664538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
    Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
    Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women.
    de Medeiros SF; Ormond CM; de Medeiros MAS; de Souza Santos N; Banhara CR; Yamamoto MMW
    Endocr Connect; 2017 Oct; 6(7):479-488. PubMed ID: 28784626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
    Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
    Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.
    Pinola P; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Ruokonen A; Puukka K; Tapanainen JS; Morin-Papunen LC
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3400-7. PubMed ID: 26192874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free androgen index and Irisin in polycystic ovary syndrome.
    Li H; Xu X; Wang X; Liao X; Li L; Yang G; Gao L
    J Endocrinol Invest; 2016 May; 39(5):549-56. PubMed ID: 26584566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype.
    Louwers YV; de Jong FH; van Herwaarden NA; Stolk L; Fauser BC; Uitterlinden AG; Laven JS
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3848-55. PubMed ID: 23861462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.